Savara Inc. (NASDAQ:SVRA) Given Average Recommendation of “Moderate Buy” by Analysts

by · The Cerbat Gem

Shares of Savara Inc. (NASDAQ:SVRA – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ten analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $8.2857.

SVRA has been the subject of a number of analyst reports. Citigroup reaffirmed an “outperform” rating on shares of Savara in a report on Thursday, October 23rd. JMP Securities increased their price target on shares of Savara from $8.00 to $11.00 and gave the stock a “market outperform” rating in a report on Thursday, October 23rd. Oppenheimer boosted their price objective on shares of Savara from $8.00 to $9.00 and gave the company an “outperform” rating in a research note on Friday, November 14th. Citizens Jmp lowered their target price on shares of Savara from $11.00 to $10.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Wednesday, October 8th.

View Our Latest Report on SVRA

Savara Stock Performance

Shares of SVRA opened at $5.36 on Friday. Savara has a 1 year low of $1.89 and a 1 year high of $5.49. The company has a debt-to-equity ratio of 0.25, a current ratio of 11.08 and a quick ratio of 11.08. The stock’s fifty day moving average price is $3.98 and its two-hundred day moving average price is $3.15. The firm has a market cap of $1.09 billion, a PE ratio of -10.72 and a beta of 0.45.

Savara (NASDAQ:SVRA – Get Free Report) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). On average, equities research analysts forecast that Savara will post -0.45 EPS for the current year.

Institutional Trading of Savara

A number of large investors have recently modified their holdings of the business. Sivia Capital Partners LLC increased its position in shares of Savara by 9.1% in the second quarter. Sivia Capital Partners LLC now owns 41,500 shares of the company’s stock worth $95,000 after purchasing an additional 3,459 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Savara by 52.3% during the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after purchasing an additional 4,626 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Savara by 17.6% in the 2nd quarter. Farther Finance Advisors LLC now owns 38,001 shares of the company’s stock worth $87,000 after purchasing an additional 5,687 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Savara by 14.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock valued at $118,000 after purchasing an additional 6,449 shares during the last quarter. Finally, Sio Capital Management LLC raised its holdings in shares of Savara by 1.0% during the 2nd quarter. Sio Capital Management LLC now owns 726,851 shares of the company’s stock valued at $1,657,000 after buying an additional 7,197 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

About Savara

(Get Free Report)

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Further Reading